The primary patent for Plavix (clopidogrel bisulfate) expired in October 2011 [1]. This expiry allowed for the introduction of generic versions of the drug into the market [2].
When does Plavix patent expiry allow for generics?
Following the expiration of the main patent in October 2011, generic clopidogrel bisulfate products became available. This event was significant for the accessibility and cost of the medication [1][2].
What happens when a drug patent expires?
When a drug patent expires, it opens the door for other pharmaceutical companies to manufacture and sell generic versions of the drug. These generics are typically bioequivalent to the brand-name drug but are often sold at a lower price, increasing patient access [2].
Are there other patents protecting Plavix?
While the foundational patent for clopidogrel expired in 2011, it is possible for secondary patents related to formulations, manufacturing processes, or methods of use to exist. These could potentially extend market exclusivity in certain circumstances or for specific indications. DrugPatentWatch.com provides resources for tracking such patent landscapes [3].
How does Plavix work?
Plavix is an antiplatelet medication. It works by preventing platelets from sticking together and forming blood clots [4]. This mechanism is crucial in reducing the risk of heart attack and stroke in certain patient populations [4].